vs
Side-by-side financial comparison of Snowflake Inc. (SNOW) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.2B, roughly 2.0× Snowflake Inc.). Zoetis runs the higher net margin — 25.3% vs -24.2%, a 49.5% gap on every dollar of revenue. On growth, Snowflake Inc. posted the faster year-over-year revenue change (28.7% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $113.6M). Over the past eight quarters, Snowflake Inc.'s revenue compounded faster (25.1% CAGR vs 4.4%).
Snowflake Inc. is an American cloud-based data platform company founded in San Mateo, California, and headquartered in Bozeman, Montana. It operates a platform that supports data analysis and simultaneous access to data sets with minimal latency. It operates on Amazon Web Services, Microsoft Azure, and Google Cloud Platform.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
SNOW vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.4B |
| Net Profit | $-294.0M | $603.0M |
| Gross Margin | 67.8% | 70.2% |
| Operating Margin | -27.2% | 31.9% |
| Net Margin | -24.2% | 25.3% |
| Revenue YoY | 28.7% | 3.0% |
| Net Profit YoY | 9.4% | 3.8% |
| EPS (diluted) | $-0.87 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $1.0B | $2.5B | ||
| Q1 25 | $986.8M | $2.2B | ||
| Q4 24 | $942.1M | $2.3B | ||
| Q3 24 | $868.8M | $2.4B | ||
| Q2 24 | $828.7M | $2.4B | ||
| Q1 24 | $774.7M | $2.2B |
| Q4 25 | $-294.0M | $603.0M | ||
| Q3 25 | $-298.0M | $721.0M | ||
| Q2 25 | $-430.1M | $718.0M | ||
| Q1 25 | $-327.5M | $631.0M | ||
| Q4 24 | $-324.3M | $581.0M | ||
| Q3 24 | $-316.9M | $682.0M | ||
| Q2 24 | $-317.0M | $624.0M | ||
| Q1 24 | $-169.4M | $599.0M |
| Q4 25 | 67.8% | 70.2% | ||
| Q3 25 | 67.5% | 71.5% | ||
| Q2 25 | 66.5% | 73.6% | ||
| Q1 25 | 66.2% | 72.0% | ||
| Q4 24 | 65.9% | 69.5% | ||
| Q3 24 | 66.8% | 70.6% | ||
| Q2 24 | 67.1% | 71.7% | ||
| Q1 24 | 68.8% | 70.6% |
| Q4 25 | -27.2% | 31.9% | ||
| Q3 25 | -29.7% | 37.0% | ||
| Q2 25 | -42.9% | 36.7% | ||
| Q1 25 | -39.2% | 36.5% | ||
| Q4 24 | -38.8% | 31.6% | ||
| Q3 24 | -40.9% | 36.6% | ||
| Q2 24 | -42.1% | 33.0% | ||
| Q1 24 | -35.6% | 34.1% |
| Q4 25 | -24.2% | 25.3% | ||
| Q3 25 | -26.0% | 30.0% | ||
| Q2 25 | -41.3% | 29.2% | ||
| Q1 25 | -33.2% | 28.4% | ||
| Q4 24 | -34.4% | 25.1% | ||
| Q3 24 | -36.5% | 28.6% | ||
| Q2 24 | -38.3% | 26.4% | ||
| Q1 24 | -21.9% | 27.4% |
| Q4 25 | $-0.87 | $1.37 | ||
| Q3 25 | $-0.89 | $1.63 | ||
| Q2 25 | $-1.29 | $1.61 | ||
| Q1 25 | $-0.98 | $1.41 | ||
| Q4 24 | $-0.98 | $1.29 | ||
| Q3 24 | $-0.95 | $1.50 | ||
| Q2 24 | $-0.95 | $1.37 | ||
| Q1 24 | $-0.51 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.1B | $3.3B |
| Total Assets | $8.2B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $2.1B | ||
| Q2 25 | $2.2B | $1.4B | ||
| Q1 25 | $2.6B | $1.7B | ||
| Q4 24 | $2.1B | $2.0B | ||
| Q3 24 | $1.3B | $1.7B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.8B | $2.0B |
| Q4 25 | $2.1B | $3.3B | ||
| Q3 25 | $2.4B | $5.4B | ||
| Q2 25 | $2.4B | $5.0B | ||
| Q1 25 | $3.0B | $4.7B | ||
| Q4 24 | $2.9B | $4.8B | ||
| Q3 24 | $4.1B | $5.2B | ||
| Q2 24 | $4.6B | $5.0B | ||
| Q1 24 | $5.2B | $5.1B |
| Q4 25 | $8.2B | $15.5B | ||
| Q3 25 | $8.2B | $15.2B | ||
| Q2 25 | $8.2B | $14.5B | ||
| Q1 25 | $9.0B | $14.1B | ||
| Q4 24 | $8.2B | $14.2B | ||
| Q3 24 | $6.9B | $14.4B | ||
| Q2 24 | $7.3B | $14.2B | ||
| Q1 24 | $8.2B | $14.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.5M | $893.0M |
| Free Cash FlowOCF − Capex | $113.6M | $732.0M |
| FCF MarginFCF / Revenue | 9.4% | 30.7% |
| Capex IntensityCapex / Revenue | 2.0% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $776.7M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.5M | $893.0M | ||
| Q3 25 | $74.9M | $938.0M | ||
| Q2 25 | $228.4M | $486.0M | ||
| Q1 25 | $432.7M | $587.0M | ||
| Q4 24 | $101.7M | $905.0M | ||
| Q3 24 | $69.9M | $951.0M | ||
| Q2 24 | $355.5M | $502.0M | ||
| Q1 24 | $344.6M | $595.0M |
| Q4 25 | $113.6M | $732.0M | ||
| Q3 25 | $58.2M | $805.0M | ||
| Q2 25 | $183.4M | $308.0M | ||
| Q1 25 | $421.4M | $438.0M | ||
| Q4 24 | $88.3M | $689.0M | ||
| Q3 24 | $64.8M | $784.0M | ||
| Q2 24 | $338.9M | $370.0M | ||
| Q1 24 | $331.5M | $455.0M |
| Q4 25 | 9.4% | 30.7% | ||
| Q3 25 | 5.1% | 33.5% | ||
| Q2 25 | 17.6% | 12.5% | ||
| Q1 25 | 42.7% | 19.7% | ||
| Q4 24 | 9.4% | 29.7% | ||
| Q3 24 | 7.5% | 32.8% | ||
| Q2 24 | 40.9% | 15.7% | ||
| Q1 24 | 42.8% | 20.8% |
| Q4 25 | 2.0% | 6.7% | ||
| Q3 25 | 1.5% | 5.5% | ||
| Q2 25 | 4.3% | 7.2% | ||
| Q1 25 | 1.1% | 6.7% | ||
| Q4 24 | 1.4% | 9.3% | ||
| Q3 24 | 0.6% | 7.0% | ||
| Q2 24 | 2.0% | 5.6% | ||
| Q1 24 | 1.7% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SNOW
| Products | $1.2B | 96% |
| Professional Services And Other | $54.5M | 4% |
| Related Party | $6.7M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
